Wells Pharmacy Network publishes an NAD+ lyophilized-vial listing aimed at prescribers. Lyophilized means freeze-dried, so this catalog entry raises different preparation and labeling questions from a premixed liquid vial. It should not be treated as a ready-to-use home injection kit simply because both products contain NAD+.
We reviewed Wells’ public product information on September 19, 2026. We did not order the preparation or test the pharmacy’s service. This supplier review focuses on the listed format, the professional guidance needed to understand it, and the distinction between a pharmacy catalog and a complete treatment plan.
Wells’ listed product requires preparation-specific guidance. Confirm who prepares it, the final label, and the complete care cost before comparing it with premixed prescriptions.
What the Wells listing actually specifies
The Wells product page lists a 1 gram vial and directs prescribers to create a provider account. That identifies the catalog presentation, but it does not establish the final liquid concentration, the patient’s directions, or the equipment that would accompany a particular prescription.
Ask whether a pharmacist or clinician supplies the product ready for use or whether another preparation step is required under professional instruction. This review does not provide mixing directions. The label-reading guide explains why a dry ingredient amount alone cannot be used to interpret a syringe marking.
Clarify who is responsible for preparation
Before accepting a prescription, ask who will prepare the final product, what materials are supplied, and how the instructions will be demonstrated. If a reader is uncomfortable handling medication or has limited dexterity, that concern should influence the care discussion before an order is sent.
Also ask which label and dates apply after preparation. A generic catalog page cannot resolve the usable period for every compounded product. Our pharmacy verification guide helps organize questions about the actual facility, preparation, and person responsible for explaining its handling.
A provider catalog is not an all-in patient offer
We did not establish a complete patient price from the public Wells listing. A clinician or telehealth service may add evaluation, prescribing, supplies, delivery, administration, and follow-up charges. The pharmacy’s product listing therefore cannot be compared directly with a bundled subscription as though both describe the same purchase.
Ask the service arranging treatment for a complete quote and identify which organization collects each payment. The cost guide explains how to compare medication quantity, care access, and recurring terms together. A larger ingredient total is not automatically a better value when preparation requirements and usability differ.
Evaluate the references for the claim you care about
Wells’ page includes references and a discussion of NAD-related biology and potential benefits. Some of that material concerns broader mechanisms or related compounds rather than a trial of the specific lyophilized product. The presence of citations is useful, but it does not mean every advertised outcome has been established for this preparation.
Our evidence overview explains how to distinguish ingredient research from product-specific clinical results. Ask the prescriber which evidence supports the proposed use for your concern and what other options deserve consideration. Compounded drugs are not FDA-approved, and a detailed supplier page does not change that status.
Make the follow-up arrangements explicit
Identify the clinician who will monitor the treatment and the pharmacy contact for questions about the product. If the medication is administered in a clinic, ask how the preparation is documented and what information is available to you. If care occurs at home, ask what live help is available when instructions are unclear.
Discuss the plan for a damaged shipment, changed label, or preparation that does not match expectations. The consultation checklist can help record responsibilities before payment. A patient should not have to decide independently which organization is responsible for resolving a medication question after it arrives.
Compare Wells with the correct alternatives
The MediVera review and Hallandale review examine premixed injection listings, while AnazaoHealth describes several supplier formats. These comparisons highlight preparation differences; they do not establish that one pharmacy’s product can replace another without clinician and pharmacist review.
For the service side of the decision, read the review of the clinic or telehealth company arranging your care, including our CoreAge Rx review of the commercial partner. This Wells review does not assert a supply relationship with that company. Its purpose is to make a specific pharmacy format understandable before you evaluate a complete treatment offer.
Follow the source
References & further reading
- Wells Pharmacy Network — lyophilized NAD+ vial
Checked September 19, 2026. Prescriber-oriented listing of a freeze-dried product. No patient preparation instructions or complete treatment price are inferred.
- FDA — compounding questions and answers
Compounded drugs are not FDA-approved or reviewed before marketing for safety, effectiveness, or quality.
- FDA — ingredients suitable for sterile compounding
Reports NAD+ injectable adverse events and ingredient-quality concerns.
- Grant et al. (2019) — human NAD+ infusion pilot
Small IV metabolism study; does not establish benefits of home injections.